ScreenerHero

ATBAntibiotice S.A.

BVB · RO · Healthcare · Drug Manufacturers - Specialty & Generic · antibiotice.ro
2.110RON+0.48%Mkt Cap: 309.48M $P/E: 211.00

Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap309.48M $
Enterprise Value384.57M $
Revenue (TTM)134.71M $
Gross Profit92.39M $
Net Income (TTM)11.31M $
Revenue/Share0.2008 USD
Last Price2.110 RON
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.4K
CountryRO
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINROATBIACNOR9
Valuation
P/E (Trailing)211.00
P/E (Forward)—
PEG3.89
EV/EBITDA21.12
EV/Revenue2.85
P/S2.29
P/B1.52
EPS (TTM)0.01
EPS (Forward)—
52W Range
1.75239% of range2.660
52W High2.660 RON
52W Low1.752 RON
Profitability
Gross Margin65.53%
Oper. Margin10.35%
EBITDA Margin13.52%
Profit Margin8.02%
ROE5.55%
ROA3.72%
Growth
Revenue Growth-4.70%
Earnings Growth-88.90%
Cash Flow & Leverage
Operating CF15.83M $
CapEx (TTM)31.16M $
FCF Margin-12.07%
FCF Yield-5.25%
Net Debt76.56M $
Net Debt/EBITDA4.20
Balance Sheet
Debt/Equity0.25
Current Ratio1.25
Quick Ratio0.79
Book Value/Sh1.386 RON
Cash/Share0.0050 RON
Dividends
Fwd Div Rate0.0200 RON
Trail. Div Rate0.0360 RON
Div. Yield0.94%
5Y Avg Yield1.25%
Payout Ratio169.89%
Ex-Div DateOct 15, 2026
Pay Date—
Splits
Last Split1.18192:1
Split DateJul 11, 2013
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.671.34M
Float227.94M
Insiders58.05%
Institutions13.63%
Technical
SMA 502.139 (-1.4%)
SMA 2002.171 (-2.8%)
Beta0.23
S&P 52W Chg18.16%
Avg Vol (30d)115.57K
Avg Vol (10d)104.44K
Technical Indicators
RSI (14)43.2
MACD-0.0090
MACD Signal-0.0029
MACD Hist.-0.0060
BB Upper2.175 RON
BB Middle2.137 RON
BB Lower2.099 RON
BB Width3.57%
ATR (14)0.0375 RON
Vol Ratio (20d)1.09x